Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith-Reference-Cited by-同舟云学术

Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith

Published:2020-12-19 Issue:3 Volume:7 Page:e16-e17
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Galli Mattia¹²^ORCID,Andreotti Felicita¹²,D’Amario Domenico¹,Crea Filippo¹²^ORCID,Porto Italo³⁴^ORCID

Affiliation:

1. Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Via della Pineta Sacchetti, 217, 00168 Rome, Italy

2. Catholic University of the Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy

3. Cardiology Unit, DICATOV – Cardiothoracic and Vascular Department, San Martino Hospital IRCCS, Largo Rosanna Benzi, 10, 16132 Genoa, Italy

4. Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Via Leon Battista Alberti, 4, 16143 Genoa, Italy

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvaa139/35002379/pvaa139.pdf

Reference10 articles.

1. Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized clinical trials;Gargiulo;Eur Heart J Cardiovasc Pharmacother,2020

2. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients;Galli;Europace,2020

3. Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: a critical appraisal;Galli;Int J Cardiol Heart Vasc,2020

4. Stent thrombosis with dual antithrombotic therapy in atrial fibrillation-ACS/PCI trials;Galli;J Am Coll Cardiol,2020

5. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials;Gargiulo;Eur Heart J,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials.;European Heart Journal - Cardiovascular Pharmacotherapy;2022-05

2. Response—letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns;European Heart Journal - Cardiovascular Pharmacotherapy;2021-03-16

3. The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?;European Heart Journal - Cardiovascular Pharmacotherapy;2020-12-26